Skip to content
WOUND AND PAIN RELIEF
INTAGESIC-MR TABLET
INTAGESIC-MR TABLET
By INTAS
Best deal on the Internet
Prescription Required
Couldn't load pickup availability
Check Availability
Rapid 3-4 Day Delivery,Tiny Extra Fee!
-
Pet Safe
-
Best Quality
-
Fast Delivery
-
Secure Payment
Collapsible content
About Product
Intagesic MR Tablet by Intas Pharmaceuticals Ltd. is a clinically formulated fixed-dose combination oral analgesic and muscle relaxant designed to address one of the most commonly encountered yet debilitating clinical presentations: acute musculoskeletal pain compounded by involuntary muscle spasm and localised inflammation. Musculoskeletal pain arising from sprains, strains, soft tissue trauma, back injuries, post-surgical oedema, and conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis involves a complex, overlapping cascade of peripheral prostaglandin-mediated inflammation, central pain sensitisation, and reflexive muscle guarding that no single drug class can fully resolve. Intagesic MR Tablet targets all three components of this triad simultaneously through its triple-action formulation: Diclofenac Sodium (50 mg) as a potent NSAID targeting peripheral and central COX-mediated inflammation, Paracetamol (325 mg) as a synergistic central analgesic and antipyretic, and Chlorzoxazone (250 mg) as a centrally acting skeletal muscle relaxant, together delivering faster, broader, and more clinically meaningful pain relief than any single agent alone. This is a Schedule H prescription medicine and must only be used under the supervision of a qualified medical professional. Animeal is proud to offer Intagesic MR Tablet as part of our curated range of trusted prescription pain management solutions.
Ingredients:
Diclofenac Sodium (50 mg): Diclofenac sodium is a potent non-selective non-steroidal anti-inflammatory drug (NSAID) that exerts its analgesic, anti-inflammatory, and mild antipyretic effects through the inhibition of both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. These enzymes catalyse the conversion of arachidonic acid to prostaglandin H2, the precursor to inflammatory prostaglandins (PGE2, PGI2) and thromboxane A2. By blocking this enzymatic step, Diclofenac reduces prostaglandin synthesis at the site of tissue injury, thereby diminishing vascular permeability, peripheral sensitisation of nociceptors, and localised oedema. At the spinal level, reduced prostaglandin availability attenuates central sensitisation, lowering the amplification of pain signals ascending to the cortex. Diclofenac has a rapid oral absorption profile with peak plasma concentrations achieved within one to two hours, making it effective for both acute and subacute pain states.
Paracetamol / Acetaminophen (325 mg): Paracetamol functions as a centrally acting analgesic and antipyretic through a mechanism distinct from classical NSAIDs. It is understood to inhibit a COX-3 variant expressed in central nervous system tissue, reducing prostaglandin-mediated pain signal amplification in the brain and spinal cord without significant peripheral anti-inflammatory activity. Additionally, paracetamol activates the descending serotonergic pain inhibitory pathways and is thought to modulate the endocannabinoid system through its active metabolite AM404. At 325 mg in this fixed-dose combination, paracetamol serves a synergistic role: it potentiates and extends Diclofenac's analgesic efficacy by addressing central pain processing, thereby reducing the effective NSAID dose required for adequate pain control and improving the overall tolerability profile of the combination. It also contributes antipyretic activity by resetting the hypothalamic thermoregulatory set-point when fever is present.
Chlorzoxazone (250 mg): Chlorzoxazone is a centrally acting benzoxazole skeletal muscle relaxant whose primary site of action is the spinal cord and supraspinal areas of the brain. It inhibits multisynaptic reflex arcs that sustain painful muscle spasm by depressing nerve impulse transmission at the polysynaptic interneurones within the spinal cord, reducing the tonic excitatory drive that maintains reflex muscle contraction. By disrupting this spinal reflex pathway, Chlorzoxazone alleviates the involuntary muscle guarding and splinting that commonly accompanies musculoskeletal injury and inflammation, restoring voluntary range of motion, reducing secondary ischaemic pain within the muscle belly, and enabling rehabilitation through physical therapy. The mild sedative effect of chlorzoxazone also contributes to patient comfort during the acute phase of injury.
Features and Benefits
Simultaneous Multi-Mechanism Pain Relief:
Intag...
Simultaneous Multi-Mechanism Pain Relief:
Intagesic MR Tablet's triple-active formulation attacks musculoskeletal pain through three distinct and complementary pharmacological pathways: peripheral prostaglandin blockade by Diclofenac, central pain processing modulation by Paracetamol, and spinal reflex-mediated muscle spasm suppression by Chlorzoxazone. This convergent targeting of pain at its peripheral origin, central amplification pathway, and musculoskeletal component delivers a faster and more complete analgesic effect than any single drug alone, alleviating discomfort more efficiently with a lower cumulative NSAID burden.
Rapid Onset of Musculoskeletal Pain Control:
The onset of pain relief with Intagesic MR Tablet is typically observed within thirty minutes to one hour of oral administration, driven by Diclofenac's rapid gastrointestinal absorption and Paracetamol's swift central action. This rapid pain control is particularly valuable in acute conditions such as sports injuries, lumbar strain, post-operative pain, and traumatic soft tissue injury, where timely analgesic intervention supports patient comfort, reduces anxiety, and facilitates earlier mobilisation and rehabilitation.
Targeted Relief of Muscle Spasm and Stiffness:
The inclusion of Chlorzoxazone as a centrally acting muscle relaxant specifically addresses the component of musculoskeletal pain that peripheral NSAIDs alone cannot resolve: involuntary muscle spasm and guarding. By relieving reflex-driven spasm at the spinal cord level, Intagesic MR restores muscle pliability, reduces secondary ischaemic pain within cramped muscle fibres, and enables patients to engage in prescribed physiotherapy and mobilisation exercises that are essential to full recovery.
Anti-Inflammatory and Oedema Reduction:
Diclofenac's COX inhibition reduces the local production of prostaglandins and prostacyclin at injured tissue sites, directly diminishing vascular hyperpermeability and fluid exudation into the interstitium. This anti-oedema effect reduces tissue swelling, the associated pressure on local nociceptors, and post-surgical fluid accumulation, reinforcing comfort and supporting faster tissue healing in the acute inflammatory phase.
Synergistic Analgesic Formulation Improves Overall Tolerability:
Because Paracetamol's central analgesic action potentiates Diclofenac's peripheral effect, the 50 mg Diclofenac dose in Intagesic MR is lower than typical standalone Diclofenac prescriptions, reducing gastrointestinal mucosal exposure and the prostaglandin-mediated disruption of gastric cytoprotection. This formulation strategy targets a more favourable tolerability profile for short-term use compared to higher-dose single NSAID regimens, while maintaining equivalent or superior analgesic efficacy.
Usage and Applications
How to Use:Intagesic MR Tablet must only be tak...
How to Use:
Intagesic MR Tablet must only be taken as directed by a qualified medical professional. The tablet should be swallowed whole with a full glass of water; do not crush, break, or chew it as this may alter the drug release profile and increase the risk of gastrointestinal irritation.
Storage Advice:
Store unopened Intagesic MR Tablets in a cool, dry place below 25 degrees Celsius, away from direct sunlight, heat, and humidity. Do not freeze. Once the strip is opened, store remaining tablets in the same conditions and in their original blister packaging to protect them from moisture. Keep this medicine out of reach of children at all times. Do not use after the expiry date printed on the strip and carton.
About the Brand:
Intas Pharmaceuticals Ltd. was founded in 1977 by Hasmukh Chudgar in Ahmedabad, India, and has grown from a single domestic enterprise into one of India's largest privately owned pharmaceutical companies, currently ranked among the top ten in the Indian pharmaceutical market with a presence in more than 85 countries across North America, Europe, Asia-Pacific, Latin America, CIS, and MENA regions. The company holds manufacturing accreditations from the world's most rigorous regulatory authorities including USFDA, EMA (EU-GMP certification, the first Indian company to receive it for biosimilars), MHRA, TGA, and WHO-GMP, and operates 17 advanced formulation, R&D, and distribution facilities globally. Intas invests approximately six to seven percent of its revenues in research and development, employing over 800 scientists and maintaining a strategic pipeline of more than 300 high-value products including biosimilars, novel drug delivery systems, and first-to-file generics across oncology, cardiovascular, central nervous system, gastroenterology, and pain management therapeutic areas. Intas's unwavering commitment to making high-quality, affordable pharmaceutical formulations accessible across regulated and emerging markets alike aligns with Animeal's commitment to offering only rigorously validated, medically credible healthcare products for every patient and pet family. Discover Intas Pharmaceuticals today.
Disclaimer:
Please note that while Intagesic MR Tablet is formulated from Chlorzoxazone (250 mg), Diclofenac Sodium (50 mg), and Paracetamol (325 mg), and is appropriate for adults with acute musculoskeletal pain and associated muscle spasm, it is a Schedule H prescription medicine and must not be purchased, dispensed, or self-administered without a valid prescription from a registered medical practitioner. It is not a substitute for appropriate medical diagnosis, physiotherapy, or prescribed rehabilitation. This product is contraindicated in pregnancy, breastfeeding, children, and individuals with active peptic ulcers, significant liver or renal impairment, severe cardiovascular disease, a history of hypersensitivity to NSAIDs or paracetamol, or nasal polyps. Long-term use without medical supervision carries significant risks of gastrointestinal bleeding, hepatic stress, and renal impairment. For patients with asthma, hypertension, diabetes, or those on anticoagulants, diuretics, lithium, or methotrexate therapy, consult your physician before initiating this product. Animeal supports your pet's health and happiness journey but does not replace the advice of a qualified veterinary professional.
